Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
AMLX holding history
Amylyx Pharmaceuticals, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AMLX overviewAll 13F holders of AMLXFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 10
- Since Q1 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −247,275−100.0% | Sold out | Holders |
| Q1 2025 | 247,275 | $875.4K | <0.1% | +62,597+33.9% | Added | Holders |
| Q4 2024 | 184,678 | $698.1K | <0.1% | −99,308−35.0% | Reduced | Holders |
| Q3 2024 | 283,986 | $920.1K | <0.1% | +283,986 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −985,114−100.0% | Sold out | Holders |
| Q4 2023 | 985,114 | $14.5M | <0.1% | −212,646−17.8% | Reduced | Holders |
| Q3 2023 | 1,197,760 | $21.9M | <0.1% | −782,420−39.5% | Reduced | Holders |
| Q2 2023 | 1,980,180 | $42.7M | 0.1% | +840,940+73.8% | Added | Holders |
| Q1 2023 | 1,139,240 | $33.4M | 0.1% | +1,139,240 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −341,064−100.0% | Sold out | Holders |
| Q3 2022 | 341,064 | $9.60M | <0.1% | −317,309−48.2% | Reduced | Holders |
| Q2 2022 | 658,373 | $12.7M | <0.1% | +73,909+12.6% | Added | Holders |
| Q1 2022 | 584,464 | $7.51M | <0.1% | +584,464 | New | Holders |